前沿速览010期| CAR-T治B淋 前沿览新知
01
表达诱导性 IL-7 和 CCL19 的抗 CD19 CAR-T 细胞治疗复发或难治性大 B 细胞淋巴瘤患者的安全性和可行性
Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma
第一作者：Lei W
Cell Discov (IF=33.5). 2024 Jan 9;10(1):5.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10774422/
02
复发/难治性滤泡性淋巴瘤成人患者接受Tisagenlecleucel治疗后获得持久缓解：ELARA试验更新
Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update
第一作者：Dreyling M
Blood (IF=20.3). 2024 Jan 9:blood.2023021567.
全文网址：https://ashpublications.org/blood/article/doi/10.1182/blood.2023021567/507096/Durable-Response-After-Tisagenlecleucel-in-Adults
03
CAR-T 细胞疗法的安全性改善：接受 CAR-T 细胞疗法的复发性或难治性 B 细胞淋巴瘤患者的病毒感染风险与预防
Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy
第一作者：Qian H
Am J Hematol (IF=12.8). 2024 Jan 10.
全文网址：https://onlinelibrary.wiley.com/doi/10.1002/ajh.27198
04
基线血清炎症蛋白可预测CAR-T 治疗弥漫大 B 细胞淋巴瘤的不良预后
Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma
第一作者：Faramand RG
Blood Cancer Discov (IF=11.2). 2024 Jan 9.
全文网址：https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-23-0056/732968/Baseline-serum-inflammatory-proteins-predict-poor
05
CAR-T 细胞治疗大 B 细胞淋巴瘤后的输血需求：预测因素和结局 (DESCAR-T研究)
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome. A DESCAR-T study
第一作者：Vic S
Blood Adv (IF=7.6). 2024 Jan 4:bloodadvances.2023011727.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023011727/506969/Transfusion-needs-after-CAR-T-cell-therapy-for
06
在实验鼠模型中比较治疗恶性血液病的抗体免疫疗法
Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model
第一作者：Albring JC
Blood Adv (IF=7.6). 2024 Jan 10:bloodadvances.2023011647.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2023011647/507107/Comparison-of-antibody-based-immunotherapeutics
07
清淋-CAR-T 细胞治疗全流程中至关重要但被低估的部分
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
第一作者：Lickefett B
Front Immunol (IF=7.3). 2023 Dec 22;14:1303935.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770848/
08
合并干燥综合症的弥漫性大 B 细胞淋巴瘤患者接受抗 CD19 CAR-T细胞治疗后，淋巴瘤和干燥综合症同时得到缓解：病例报告
Concurrent remission of lymphoma and Sjögren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report
第一作者：Sheng L
Front Immunol (IF=7.3). 2023 Dec 19;14:1298815.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10762793/
09
CAR-T细胞治疗淋巴瘤：新的应用场景与未来方向
Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions
第一作者：Benevolo Savelli C
Cancers (Basel) (IF=5.2). 2023 Dec 21;16(1):46.
全文网址：https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10778255/
10
接受Axicabtagene ciloleucel和预防性皮质类固醇治疗的大B细胞淋巴瘤患者的长期结局
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
第一作者：Oluwole OO
Bone Marrow Transplant (IF=4.8). 2024 Jan 4.
全文网址：https://www.nature.com/articles/s41409-023-02169-z
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.1-16 valid until 2026.1
供稿与审核：临床开发与医学部